Equinox Meditech Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
- Paid Up Capital ₹ 4.50 M
- Company Age 13 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.00 M
- Revenue Growth 4.49%
- Profit Growth 92.44%
- Ebitda 99.04%
- Net Worth -1.35%
- Total Assets -9.36%
About Equinox Meditech
Equinox Meditech Private Limited (EMPL) is a Private Limited Indian Non-Government Company incorporated in India on 10 March 2011 and has a history of 13 years and 11 months. Its registered office is in New Delhi, Delhi, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 4.50 M.
The company currently has active open charges totaling ₹3.00 M.
Rajesh Garg and Monika Garg serve as directors at the Company.
Company Details
- Location
New Delhi, Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24232DL2011PTC215600
- Company No.
215600
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Mar 2011
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
What products or services does Equinox Meditech Private Limited offer?
Equinox Meditech Private Limited offers a wide range of products and services, including PU Foam, Coir & Jute Mattresses, Air Mattresses.
Who are the key members and board of directors at Equinox Meditech?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajesh Garg  | Director | 10-Mar-2011 | Current |
| Monika Garg | Director | 10-Mar-2011 | Current |
Financial Performance of Equinox Meditech.
Equinox Meditech Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 4.49% increase. The company also saw a substantial improvement in profitability, with a 92.44% increase in profit. The company's net worth dipped by a decrease of 1.35%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Equinox Meditech?
In 2023, Equinox Meditech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Equinox Overseas Private LimitedRajesh Garg and Monika Garg are mutual person
Charges (Loans)
₹0.30 Cr
₹0
Charges Breakdown by Lending Institutions
- Others : 0.30 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 10 Jun 2013 | Others | ₹3.00 M | Open |
How Many Employees Work at Equinox Meditech?
Unlock and access historical data on people associated with Equinox Meditech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Equinox Meditech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Equinox Meditech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
